{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T10:37:16Z","timestamp":1772620636491,"version":"3.50.1"},"reference-count":7,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"vor","delay-in-days":365,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jtoelsevier.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.jtho.2016.03.001","type":"journal-article","created":{"date-parts":[[2016,5,20]],"date-time":"2016-05-20T10:23:26Z","timestamp":1463739806000},"page":"e78-e80","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["EGFR Status in Mesothelioma: Possible Implications for the Efficacy of Anti-EGFR and Anti-MET Therapies"],"prefix":"10.1016","volume":"11","author":[{"given":"Sandra","family":"Salvi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena","family":"Varesano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Boccardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Louis","family":"Ravetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier Aldo","family":"Canessa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Pia","family":"Pistillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Ferro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco","family":"Fedeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvio","family":"Roncella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2016.03.001_bib1","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1016\/j.jtho.2015.10.019","article-title":"MET gene status in malignant mesothelioma by fluorescent in\u00a0situ hybridization","volume":"11","author":"Varesano","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2016.03.001_bib2","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1136\/jcp.2009.066548","article-title":"EGFR fluorescence in situ hybridization assay: guidelines for application to non-small-cell lung cancer","volume":"62","author":"Varella-Garcia","year":"2009","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.jtho.2016.03.001_bib3","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/JTO.0000000000000355","article-title":"Erlotinib efficacy in NSCLC patients with high polysomy of chromosome 7 and EGFR\/KRas wild-type tumors","volume":"10","author":"Toffalorio","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2016.03.001_bib4","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1097\/JTO.0b013e318215a07d","article-title":"Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy","volume":"6","author":"Brevet","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2016.03.001_bib5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12885-015-1019-1","article-title":"MET FISH-positive status\u00a0predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with EGFR mutation","volume":"15","author":"Noro","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jtho.2016.03.001_bib6","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1158\/0008-5472.CAN-10-1623","article-title":"Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors","volume":"71","author":"Qi","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2016.03.001_bib7","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/carcin\/bgp097","article-title":"Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells","volume":"30","author":"Kawaguchi","year":"2009","journal-title":"Carcinogenesis"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086416004457?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086416004457?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T23:24:41Z","timestamp":1536708281000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086416004457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":7,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S1556086416004457"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2016.03.001","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EGFR Status in Mesothelioma: Possible Implications for the Efficacy of Anti-EGFR and Anti-MET Therapies","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2016.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2015.10.019","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}